proton pump inhibitors
Irreversible H⁺/K⁺-ATPase inhibitors — the most effective acid suppression. Take 30–60 min before breakfast (before dinner too if BID). Clear indications: erosive oesophagitis, Barrett’s, peptic ulcer and H. pylori therapy, ulcer bleeding, gastroprotection with NSAIDs/antithrombotics in high-risk patients, EoE. Review every long-term prescription — try to stop or step down at least yearly unless Barrett’s, LA grade C/D oesophagitis or prior GI bleeding. Long-term harms are mostly observational; the only one confirmed in an RCT is enteric infection.
mechanism
Prodrugs activated in the acid of the parietal cell canaliculus → bind only active pumps → must be taken before a meal, when pumps are stimulated. Full effect takes 3–5 days.
dosing
| indication | regimen | duration |
|---|---|---|
| uninvestigated GERD (no alarm features) | standard dose daily before breakfast | 8-week trial → then try to stop |
| erosive oesophagitis LA A/B | standard dose daily | heal, then step down/on-demand |
| erosive oesophagitis LA C/D, Barrett’s | BID to heal, then lowest effective daily dose | indefinite |
| non-erosive reflux | on-demand or intermittent | — |
| refractory symptoms | optimise timing, then BID | objective testing (gastro-oesophageal reflux disease) |
| peptic ulcer | daily | duration by cause; stop after healing if H. pylori cured and NSAID stopped |
| H. pylori eradication | BID with antibiotics | 14 days (peptic ulcer disease and H. pylori) |
| ulcer bleed, high-risk stigmata | high-dose IV × 72 h → BID to day 14 → daily | regimen → upper GI bleeding |
| gastroprotection (prior ulcer bleed on antiplatelet/anticoagulant/NSAID) | daily | while the drug continues |
| EoE | standard–high dose | 8 weeks → biopsy (eosinophilic oesophagitis) |
Standard daily doses: pantoprazole 40 mg, omeprazole 20 mg, esomeprazole 20–40 mg, lansoprazole 30 mg, rabeprazole 20 mg. Oral is as good as IV whenever the patient can swallow.
key points
- Deprescribing: no ongoing indication → stop or step down; most GERD patients can try stopping once a year (Choosing Wisely Canada). Taper or switch to on-demand to blunt rebound acid hypersecretion.
- Clopidogrel: omeprazole and esomeprazole inhibit CYP2C19 → use pantoprazole (antiplatelets).
- Before H. pylori breath or stool testing: stop PPI 2 weeks (H2RA allowed).
- No benefit adding a PPI to all inpatients (“stress ulcer prophylaxis”) outside ICU risk criteria.
- Vonoprazan (potassium-competitive acid blocker) — faster, longer acid suppression, not meal-dependent; used in H. pylori regimens and erosive oesophagitis; limited availability in Canada.
adverse effects
COMPASS (2019): 17 598 patients randomised to pantoprazole vs placebo for ~3 years — no difference in pneumonia, fracture, CKD, dementia, cardiovascular events or death; only enteric infections were higher (1.4% vs 1.0%).
Observational associations (causality unproven; matter in frail or high-risk patients):
- C. difficile and other enteric infections
- hypomagnesaemia (→ hypokalaemia, hypocalcaemia) — check Mg²⁺ on long-term use with diuretics
- B12 and iron malabsorption
- microscopic colitis (chronic diarrhoea)
- fractures, pneumonia, acute interstitial nephritis
- common minor effects: headache, abdominal pain, diarrhoea — try another PPI
ACG 2022 advice to patients: benefits of a PPI for a real indication outweigh these theoretical risks.
Ontario
- Ontario: ODB lists generic PPIs (some under Limited Use) → LU search.
Prepared 2026-10-28. Not yet verified — check every number against the sources.